Non‑coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies (Review)
- Authors:
- Georgios Drillis
- Maria Goulielmaki
- Demetrios A. Spandidos
- Sofia Aggelaki
- Vassilios Zoumpourlis
-
Affiliations: 1st Internal Medicine Clinic, Medical School, Laiko University Hospital of Athens, 115 27 Athens, Greece, Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 116 35 Athens, Greece, Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece, Oncology Unit, Medical School, University of Crete, 71003 Heraklion, Greece - Published online on: March 18, 2021 https://doi.org/10.3892/ol.2021.12654
- Article Number: 393
-
Copyright: © Drillis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Bardia A and Seifter E: Johns Hopkins Patients' Guide to Lymphoma. 1st edition. Jones and Bartlett Publishers, Inc.; pp. 1382010 | |
The Lymphoma Guide, . Information for Patients and Caregivers. Leukemia and Lymphoma Society; New York, USA: 2013 | |
World Health Organization: World Cancer Report 2014. IARC Publications; Lyon, France: pp. 348–528. 2014 | |
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016. View Article : Google Scholar : PubMed/NCBI | |
Coiffier B: Monoclonal antibody as therapy for malignant lymphomas. C R Biol. 329:241–254. 2006. View Article : Google Scholar : PubMed/NCBI | |
Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
Küppers R, Klein U, Hansmann ML and Rajewsky K: Cellular origin of human B-cell lymphomas. N Engl J Med. 341:1520–1529. 1999. View Article : Google Scholar : PubMed/NCBI | |
National Cancer Institute, . General information about adult Hodgkin Lymphoma. 2014. | |
National Cancer Institute, . General Information about adult Non-Hodgkin Lymphoma. 2014. | |
Hu L, Luo D, Zhou T, Tao Y, Feng J and Mei S: The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis. Environ Pollut. 231:319–328. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yang L, Dong J, Jiang S, Shi W, Xu X, Huang H, You X and Liu H: Red and processed meat consumption increases risk for Non-Hodgkin lymphoma: A PRISMA-compliant meta-analysis of observational studies. Medicine. 94:e17292015. View Article : Google Scholar : PubMed/NCBI | |
Solimini AG, Lombardi AM, Palazzo C and De Giusti M: Meat intake and non-Hodgkin lymphoma: A meta-analysis of observational studies. Cancer Causes Control. 27:595–606. 2016. View Article : Google Scholar : PubMed/NCBI | |
National Cancer Institute, . Cancer Stat Facts: Non-Hodgkin Lymphoma. 2014. | |
Marcus R, Sweetenham J and Williams L: Lymphoma: Pathology, diagnosis and treatment (2nd edition). Cambridge Medicine. 3262014. | |
Tepper JE, Niederhuber JO, Armitage JH, Doroshow MB and Kastan JE: Childhood Lymphoma (5th edition): Abeloff's Clinical Oncology. Chapter. 97. Elsevier Inc.; 2014 | |
Kamper-Jørgensen M, Rostgaard KG, Zahm SH, Cozen W, Smedby KE, Sanjosé S, Chang ET, Zheng T, La Vecchia C, Serraino D, et al: Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: A pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol. 24:2245–2255. 2013. View Article : Google Scholar : PubMed/NCBI | |
Manli JN, Bennani N and Feldman AL: Lymphoma classification update: T-cell lymphomas, Hodgkin lymphoma, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 10:239–249. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sheikhpour R, Pourhosseini F, Neamatzadeh H and Karimi R: Immunophenotype evaluation of Non-Hodgkin's lymphomas. Med J Islam Repub Iran. 31:1212017. View Article : Google Scholar : PubMed/NCBI | |
Gibb EA, Brown CJ and Lam WL: The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI | |
Taft RJ, Pang KC, Mercer TR, Dinger M and Mattick JS: Non-coding RNAs: Regulators of disease. J Pathol. 220:126–139. 2010. View Article : Google Scholar : PubMed/NCBI | |
Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI | |
Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA and Prensner JR: Coordinated regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell. 20:187–199. 2011. View Article : Google Scholar : PubMed/NCBI | |
He Y, Vogelstein B, Velculescu VE, Papadopoulos N and Kinzler KW: The antisense transcriptomes of human cells. Science. 322:1855–1857. 2008. View Article : Google Scholar : PubMed/NCBI | |
Faulkner GJ, Kimura Y, Daub CO, Wani S, Plessy C and Irvine KM: The regulated retrotransposon transcriptome of mammalian cells. Nat Genet. 41:563–571. 2009. View Article : Google Scholar : PubMed/NCBI | |
Pérez-Vera P, Reyes-León A and Fuentes-Pananá EM: Signaling proteins and transcription factors in normal and malignant early B cell development. Bone Marrow Res. 2011:5027512011. View Article : Google Scholar : PubMed/NCBI | |
Alberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Molecular Biology of the Cell. T cells and B cells derive their names from the organs in which they develop. T cells develop in the thymus and B cells, in mammals, develop in the bone marrow in adults or the liver in fetuses. Garland Science; New York, NY: pp. pg13672002 | |
Petri A, Dybkaer K, Bogsted M, Thrue CA, Hagedorn PH, Schmitz A, Bodker JS, Johnsen HE and Kauppinen S: Long noncoding RNA expression during Human B-cell development. PLoS One. 10:e01382362015. View Article : Google Scholar : PubMed/NCBI | |
Herzog S, Reth M and Jumaa H: Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 9:195–205. 2009. View Article : Google Scholar : PubMed/NCBI | |
Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, Vizgoft EK, Dunne R, Pimlott L, Young GP, et al: Colorectal Neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer. 2:829–840. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ellis BC, Molloy PL and Graham LD: CRNDE: A long NonCoding RNA involved in CanceR, neurobiology, and development. Front Genet. 3:2702012. View Article : Google Scholar : PubMed/NCBI | |
Ellis BC, Graham LD and Molloy PL: CRNDE, a long noncoding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta. 1843:372–386. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chen CZ, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science. 303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI | |
de Yebenes VG, Belver L, Pisano DG, Gonzalez S, Villasante A, Croce C, He L and Ramiro AR: miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med. 205:2199–206. 2008. View Article : Google Scholar : PubMed/NCBI | |
Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R and Papavasiliou FN: MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 28:621–629. 2008. View Article : Google Scholar : PubMed/NCBI | |
Smith A, Howell D, Patmore R, Jack A and Roman E: Incidence of haematological malignancy by sub-type: A report from the Haematological malignancy research network. Br J Cancer. 105:1684–1692. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li S, Young KH and Medeiros LJ: Diffuse large B-cell lymphoma. Pathology. 50:74–87. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 105:13520–13525. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sukswai N, Lyapichev K, Khoury JD and Medeiros LJ: Diffuse large B-cell lymphoma variants: An update. Pathology. 52:53–67. 2019. View Article : Google Scholar : PubMed/NCBI | |
Shimada K, Hayakawa F and Kiyoi H: Biology and management of primary effusion lymphoma. Blood. 132:1879–1888. 2018. View Article : Google Scholar : PubMed/NCBI | |
Cheng Y, Xiao Y, Zhou R, Liao Y, Zhou J and Ma X: Prognostic significance of Helicobacter pylori-infection in gastric diffuse large B-cell lymphoma. BMC Cancer. 19:8422019. View Article : Google Scholar : PubMed/NCBI | |
Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Hsu C, Wu MS, Tzeng YS, Tsai HJ, Wang HP and Cheng AL: Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 4:e2202014. View Article : Google Scholar : PubMed/NCBI | |
Abramson JS: Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Cancer. 125:3111–3120. 2019. View Article : Google Scholar : PubMed/NCBI | |
Chavez JC and Locke FL: CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 31:135–146. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu Y and Barta SK: Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 94:604–616. 2019. View Article : Google Scholar : PubMed/NCBI | |
Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO, Thiere M, Loeffler M, Klapper W, Pfreundschuh M, et al: MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 142:732–744. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat JS and Hatton CS: Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 13:1248–1260. 2009. View Article : Google Scholar : PubMed/NCBI | |
Caramuta S, Lee L, Ozata DM, Akçakaya P, Georgii-Hemming P, Xie H, Amini RM, Lawrie CH, Enblad G, Larsson C, et al: Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J. 3:e1522013. View Article : Google Scholar : PubMed/NCBI | |
Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD, Brown PJ, Troussard X, Mossafa H, Enver T, et al: MicroRNA expression in lymphocyte development and malignancy. Leukemia. 22:1440–1446. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zhong H, Xu L, Zhong JH, Xiao F, Liu Q, Huang HH and Chen FY: Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. Exp Ther Med. 3:763–770. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhou K, Feng X, Wang Y, Liu Y, Tian L, Zuo Z, Yi S, Wei X, Song Y and Qiu L: miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11. Exp Hematol. 58:27–34. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, Coiffier B, Magaud JP, Berger F, Salles GA and Traverse-Glehen A: MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol. 156:279–281. 2012. View Article : Google Scholar : PubMed/NCBI | |
Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, et al: Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 305:59–67. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 28:655–661. 2010. View Article : Google Scholar : PubMed/NCBI | |
He M, Gao L, Zhang S, Tao L, Wang J, Yang J and Zhu M: Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer. 17:431–441. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jia YJ, Liu ZB, Wang WG, Sun CB, Wei P, Yang YL, You MJ, Yu BH, Li XQ and Zhou XY: HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. Leukemia. 32:703–711. 2017. View Article : Google Scholar : PubMed/NCBI | |
Gu L, Song G, Chen L, Nie Z, He B, Pan Y, Xu Y, Li R, Gao T, Cho WC and Wang S: Inhibition of miR-21 induces biological and behavioral alterations in diffuse large B-cell lymphoma. Acta Haematol. 130:87–94. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zheng Z, Li X, Zhu Y, Gu W, Xie X and Jiang J: Prognostic significance of miRNA in patients with diffuse large B-cell lymphoma: A meta-analysis. Cell Physiol Biochem. 39:1891–1904. 2016. View Article : Google Scholar : PubMed/NCBI | |
Pillar N, Bairey O, Goldschmidt N, Fellig Y, Rosenblat Y, Shehtman I, Haguel D, Raanani P, Shomron N and Siegal T: MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma. Oncotarget. 8:86020–86030. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al: Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bomben R, Gobessi S, Dal Bo M, Volinia M, Marconi D, Tissino E, Benedetti D, Zucchetto A, Rossi D, Gaidano G, et al: The miR-17~92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia. 26:1584–1593. 2012. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Ferracin M, Cimmino A, Di Leva GD, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ferrajoli A, Shanafelt TD, Ivan C, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, et al: Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 122:1891–1899. 2013. View Article : Google Scholar : PubMed/NCBI | |
Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, et al: Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 125:1137–1145. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M, Saccenti E, Lupini L, Grilli A, De Angeli C, et al: MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 9:1232010. View Article : Google Scholar : PubMed/NCBI | |
Khare D, Goldschmidt N, Bardugo A, Gur-Wahnon D, Ben-Dov IZ and Avni B: Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance. PLoS One. 12:e01877222017. View Article : Google Scholar : PubMed/NCBI | |
Meng Y, Quan L and Liu A: Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions. Gene. 642:205–211. 2018. View Article : Google Scholar : PubMed/NCBI | |
Song G, Gu L, Li J, Tang Z, Liu H, Chen B, Sun X, He B, Pan Y, Wang S and Cho WC: Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol. 93:1735–1743. 2014. View Article : Google Scholar : PubMed/NCBI | |
Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, et al: MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J. 7:6542017. View Article : Google Scholar : PubMed/NCBI | |
Thompson MA, Edmonds MD, Liang S, McClintock-Treep S, Wang X, Li S and Eischen CM: miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. Human Pathol. 50:118–126. 2016. View Article : Google Scholar | |
Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, et al: MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 118:5550–5558. 2011. View Article : Google Scholar : PubMed/NCBI | |
Peng W, Wu J and Feng J: LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Clin Exp Med. 17:1–8. 2017. View Article : Google Scholar : PubMed/NCBI | |
Blume CJ, Hotz-Wagenblatt A, Hullein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, et al: p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 29:2015–2023. 2015. View Article : Google Scholar : PubMed/NCBI | |
Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, et al: A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 142:409–419. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, Huarte M, Zhan M, Becker KG and Gorospe M: LincRNA-p21 suppresses target mRNA translation. Mol Cell. 47:648–655. 2012. View Article : Google Scholar : PubMed/NCBI | |
Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ and Medeiros LJ: Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. The Am J Pathol. 169:2171–2180. 2006. View Article : Google Scholar : PubMed/NCBI | |
Mourtada-Maarabouni M and Williams GT: Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk. 14:468–473. 2014. View Article : Google Scholar : PubMed/NCBI | |
Coccia EM, Cicala C, Charlesworth A, Ciccarelli C, Rossi GB, Philipson L and Sorrentino V: Regulation and expression of a growth arrest-specific gene (gas5) during growth, differentiation, and development. Mol Cell Biol. 12:3514–3521. 1992. View Article : Google Scholar : PubMed/NCBI | |
Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F and Williams GT: GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 28:195–208. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nakamura Y, Takahashi N, Kakegawa E, Yoshida K, Ito Y, Kayano H, Niitsu N, Jinnai I and Bessho M: The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. Cancer Genet Cytogenet. 182:144–149. 2008. View Article : Google Scholar : PubMed/NCBI | |
Qiao HP, Gao WS, Huo JX and Yang ZS: Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pac J Cancer Prev. 14:1077–1082. 2013. View Article : Google Scholar : PubMed/NCBI | |
Shi X, Sun M, Liu H, Yao Y, Kong R, Chen F and Song Y: A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. Mol Carcinog. 54 (Suppl 1):E1–E12. 2015. View Article : Google Scholar : PubMed/NCBI | |
Williams GT, Mourtada-Maarabouni M and Farzaneh F: A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochem Soc Trans. 39:482–486. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mourtada-Maarabouni M, Hasan AM, Farzaneh F and Williams GT: Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol. 78:19–28. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ronchetti D, Agnelli L, Taiana E, Galletti S, Manzoni M, Todoerti K, Musto P, Strozzi F and Neri A: Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget. 7:14814–14830. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kino T, Hurt DE, Ichijo T, Nader N and Chrousos GP: Noncoding RNA gas5 is a growth arrest- and starvationassociated repressor of the glucocorticoid receptor. Sci Signal. 3:ra82010. View Article : Google Scholar : PubMed/NCBI | |
Conde L, Riby J, Zhang J, Bracci PM and Skibola CF: Copy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphoma. PLoS One. 9:e1053822014. View Article : Google Scholar : PubMed/NCBI | |
Lu Z, Pannunzio NR, Greisman HA, Casero D, Parekh C and Lieber MR: Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations. Blood. 126:1730–1731. 2015. View Article : Google Scholar : PubMed/NCBI | |
Peng W and Feng J: Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomed Pharmacother. 77:65–71. 2016. View Article : Google Scholar : PubMed/NCBI | |
Trimarchi T, Bilal E, Ntziachristos P, Fabbri G, DallaFavera R, Tsirigos A and Aifantis I: Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 158:593–606. 2014. View Article : Google Scholar : PubMed/NCBI | |
Peng W, Fan H, Wu G, Wu J and Feng J: Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. Clin Exp Med. 16:177–182. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ono R, Kobayashi S, Wagatsuma H, Aisaka K, Kohda T, Kaneko-Ishino T and Ishino F: A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics. 73:232–237. 2001. View Article : Google Scholar : PubMed/NCBI | |
Li CM, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, Szabolcs M, Klinakis A and Tycko B: PEG10 is a c-MYC target gene in cancer cells. Cancer Res. 66:665–672. 2006. View Article : Google Scholar : PubMed/NCBI | |
Peng W, Wu J and Feng J: Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacother. 79:188–193. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hammerle M, Gutschner T, Uckelmann H, Ozgur S, Fiskin E, Gross M, Skawran B, Geffers R, Longerich T, Breuhahn K, et al: Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology. 58:1703–1712. 2013. View Article : Google Scholar : PubMed/NCBI | |
Xie H, Ma H and Zhou D: Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int. 2013:1361062013. View Article : Google Scholar : PubMed/NCBI | |
Peng W, Gao W and Feng J: Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 31:3462014. View Article : Google Scholar : PubMed/NCBI | |
Yan Y, Han J, Li Z, Yang H, Sui Y and Wang M: Elevated RNA expression of long noncoding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Mol Med Rep. 13:5125–5131. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hallek M, Shanafelt TD and Eichhorst B: Chronic lymphocytic leukaemia. Lancet. 391:1524–1537. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tresckow JV, Eichhorst B, Bahlo J and Hallek M: The treatment of chronic lymphatic leukemia. Dtsch Arztebl Int. 116:41–46. 2019.PubMed/NCBI | |
Choi SM and O'Malley DP: Diagnostically relevant updates to the WHO classification of lymphoid neoplasms. Ann Diagn Pathol. 37:67–74. 2018. View Article : Google Scholar : PubMed/NCBI | |
Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH and Catovsky D: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 8:1640–1645. 1994.PubMed/NCBI | |
Hallek M: Chronic lymphocytic leukemia: Update on diagnosis, risk stratification, and treatment. Am J Hematol. 92:946–965. 2017. View Article : Google Scholar : PubMed/NCBI | |
Deans JP and Polyak MJ: FMC7 is an epitope of CD20. Blood. 111:24922008. View Article : Google Scholar : PubMed/NCBI | |
Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, Conticello C, Villari L and Di Raimondo F: CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 33:1212–1216. 2009. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG and Keating MJ: Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 119:1162–1172. 2012. View Article : Google Scholar : PubMed/NCBI | |
Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, et al: MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 116:945–952. 2010. View Article : Google Scholar : PubMed/NCBI | |
Visone R, Veronese A, Balatti V and Croce CM: MiR-181b: New perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget. 3:195–202. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, et al: MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 124:546–554. 2014. View Article : Google Scholar : PubMed/NCBI | |
Caivano A, La Rocca F, Simeon V, Girasole M, Dinarelli S, Laurenzana I, De Stradis A, De Luca L, Trino S, Traficante A, et al: MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies-a short report. Cell Oncol (Dordr). 40:97–103. 2017. View Article : Google Scholar : PubMed/NCBI | |
Filip AA, Grenda A, Popek S, Koczkodaj D, Wojnowska MM, Budzyński M, Szczepanek EW, Zmorzyński S, Karczmarczyk A and Giannopoulos K: Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. Ann Hematol. 96:33–50. 2017. View Article : Google Scholar : PubMed/NCBI | |
Gaidano G, Foà R and Dalla-Favera R: Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 122:3432–3438. 2012. View Article : Google Scholar : PubMed/NCBI | |
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M and Lichter P: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 343:1910–1916. 2000. View Article : Google Scholar : PubMed/NCBI | |
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR16 induce apoptosis by targetinag BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI | |
Fathullahzadeh S, Mirzaei H, Honardoost MA, Sahebkar A and Salehi M: Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther. 23:327–332. 2016. View Article : Google Scholar : PubMed/NCBI | |
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G and Dalla-Favera R: The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 17:28–40. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grander D and Corcoran MM: DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 315:2941–2952. 2009. View Article : Google Scholar : PubMed/NCBI | |
Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Filarsky K, Idler I, Zucknick M, Caudron-Herger M, Oakes C, et al: Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet. 9:e10033732013. View Article : Google Scholar : PubMed/NCBI | |
Baer C, Oakes CC and Ruppert AS: Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int J Cancer. 137:1352–1361. 2015. View Article : Google Scholar : PubMed/NCBI | |
Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A and Lawrence JB: An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell. 33:717–726. 2009. View Article : Google Scholar : PubMed/NCBI | |
Naganuma T, Nakagawa S, Tanigawa A, Sasaki YF, Goshima N and Hirose T: Alternative 3′-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. EMBO J. 31:4020–4034. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps TJ and Croce CM: Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 7:54174–54182. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ishii N, Ozaki K, Sato H, Mizuno H, Saito S, Takahashi A, Miyamoto Y, Ikegawa S, Kamatani N, Hori M, et al: Identification of a novel noncoding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 51:1087–1099. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ip JY and Nakagawa S: Long non-coding RNAs in nuclear bodies. Dev Growth Differ. 54:44–54. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sheik Mohamed J, Gaughwin PM, Lim B, Robson P and Lipovich L: Conserved long noncoding RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells. RNA. 16:324–337. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ferreira PG, Jares P, Rico D, Gomez-López G, Martínez-Trillos A, Villamor N, Ecker S, Gonzalez-Perez A, Knowles DG, Monlong J, et al: Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 24:212–226. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ronchetti D, Manzoni M, Agnelli L and Vinci C: lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer J. 6:e4682016. View Article : Google Scholar : PubMed/NCBI | |
Park SM, Park SJ, Kim HJ, Kwon OH, Kang TW, Sohn HA, Kim SK, Moo Noh S, Song KS, Jang SJ, et al: A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis. Exp Mol Med. 45:e312013. View Article : Google Scholar : PubMed/NCBI | |
Wang LQ, Wong KY, Li ZH and Chim CS: Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. Oncotarget. 7:82400–82410. 2016. View Article : Google Scholar : PubMed/NCBI | |
Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI | |
Tam W: Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene. 274:157–167. 2001. View Article : Google Scholar : PubMed/NCBI | |
Elton TS, Selemon H, Elton SM and Parinandi NL: Regulation of the MIR155 host gene in physiological and pathological processes. Gene. 532:1–12. 2013. View Article : Google Scholar : PubMed/NCBI | |
Stamatopoulos B, Van Damme M, Crompot E, Dessars B, Housni HE, Mineur P, Meuleman N, Bron D and Lagneaux L: Opposite prognostic significance of cellular and serum circulating MicroRNA-150 in patients with chronic lymphocytic leukemia. Mol Med. 21:123–133. 2015. View Article : Google Scholar : PubMed/NCBI | |
Georgiadis P, Liampa I, Hebels DG, Krauskopf J, Chatziioannou A, Valavanis I, de Kok TMCM, Kleinjans JCS, Bergdahl IA, Melin B, et al: Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis. BMC Genomics. 18:7282017. View Article : Google Scholar : PubMed/NCBI | |
Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, et al: Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological Oncol. 35:397–407. 2017. View Article : Google Scholar | |
Boughan K and Caimi PF: Follicular lymphoma: Diagnostic and prognostic considerations in initial treatment approach. Curr Oncol Rep. 21:632019. View Article : Google Scholar : PubMed/NCBI | |
Pan Y, Li H, Guo Y, Luo Y, Li H, Xu Y, Deng J and Sun B: A pilot study of long noncoding RNA expression profiling by microarray in follicular lymphoma. Gene. 577:132–139. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES and Calvo KR: MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica. 97:586–594. 2012. View Article : Google Scholar : PubMed/NCBI | |
Arribas AJ, Campos-Martín Y, Gómez-Abad C, Algara P, Sánchez-Beato M, Rodriguez-Pinilla MS, Montes-Moreno S, Martinez N, Alves-Ferreira J, Piris MA and Mollejo M: Nodal marginal zone lymphoma: Gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood. 119:e9–e21. 2012. View Article : Google Scholar : PubMed/NCBI | |
Jares P, Colomer D and Campo E: Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 122:3416–3423. 2012. View Article : Google Scholar : PubMed/NCBI | |
Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, Sargent RL, Espinet B, Climent F, Jacobs SA, et al: In situ mantle cell lymphoma: Clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 97:270–278. 2012. View Article : Google Scholar : PubMed/NCBI | |
Navarro A, Beà S, Fernández V, Prieto M, Salaverria I, Jares P, Hartmann E, Mozos A, López-Guillermo A, Villamor N, et al: MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res. 69:7071–7078. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK, Eckhardt SG and Robinson WA: Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 112:822–829. 2008. View Article : Google Scholar : PubMed/NCBI | |
Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, Liu Z, Lachel CM, Deffenbacher K, Greiner TC, et al: Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood. 119:4939–4948. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Sehgal L, Jain N, Khashab T, Mathur R and Samaniego F: LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 14:3462016. View Article : Google Scholar : PubMed/NCBI | |
Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, et al: The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 39:925–938. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yang F, Yi F, Han X, Du Q and Liang Z: MALAT-1 interacts with hnRNP C in cell cycle regulation. FEBS Lett. 587:3175–3181. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, Chang JG and Liu TC: MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer. 14:8092014. View Article : Google Scholar : PubMed/NCBI | |
Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U and Dalay N: Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 431:255–259. 2014. View Article : Google Scholar : PubMed/NCBI | |
Li B, Chen P, Qu J, Shi L and Zhuang W, Fu J, Li J, Zhang X, Sun Y and Zhuang W: Activation of LTBP3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma. J Biol Chem. 289:29365–29375. 2014. View Article : Google Scholar : PubMed/NCBI | |
Matsumoto T and Abe M: TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone. 48:129–134. 2011. View Article : Google Scholar : PubMed/NCBI | |
Arakawa F, Kimura Y, Yoshida N, Miyoshi H, Doi A, Yasuda K, Nakajima K, Kiyasu J, Niino D, Sugita Y, et al: Identification of miR-15b as a transformation-related factor in mantle cell lymphoma. Int J Oncol. 48:485–492. 2016. View Article : Google Scholar : PubMed/NCBI | |
Roisman A, Huamán Garaicoa F, Metrebian F, Narbaitz M, Kohan D, García Rivello H, Fernandez I, Pavlovsky A, Pavlovsky M, Hernández L and Slavutsky I: SOXC and miR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. Genes Chromosomes Cancer. 55:531–540. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, et al: microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 115:2630–2639. 2010. View Article : Google Scholar : PubMed/NCBI | |
Di Lisio L, Gomez-López G, Sánchez-Beato M, Gómez-Abad C, Rodrıguez ME, Villuendas R, Ferreira BI, Carro A, Rico D, Mollejo M, et al: Mantle cell lymphoma: Transcriptional regulation by microRNAs. Leukemia. 24:1335–1342. 2010. View Article : Google Scholar : PubMed/NCBI | |
Husby S, Ralfkiaer U, Garde C, Zandi R, Ek S, Kolstad A, Jerkeman M, Laurell A, Räty R, Pedersen LB, et al: miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. Blood. 125:2669–2677. 2015. View Article : Google Scholar : PubMed/NCBI | |
Molyneux E, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison C, Israels T and Bailey S: Burkitt's lymphoma. Lancet. 379:1234–1244. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hoffman R: Hematology: Basic Principles and Practice (5th edition). Churchill Livingstone/Elsevier; Philadelphia, PA: pp. 1304–1305. 2009 | |
Smardova J, Grochova D, Fabian P, Moulis M, Smarda J, Falkova I, Ravcukova B, Vankova J and Vasova I: An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication. Oncol Rep. 20:773–778. 2008.PubMed/NCBI | |
Liu D, Shimonov J, Primanneni S, Lai Y, Ahmed T and Seiter K: t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia. Mol Cancer. 6:352007. View Article : Google Scholar : PubMed/NCBI | |
Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, Reina San-Martin B, Heidkamp G, Schwickert TA, et al: MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity. 28:630–638. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI | |
Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, et al: MYC translocation-negative classical Burkitt lymphoma cases: An alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 216:440–450. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, De Falco G, Githanga J, Horn H, Nyagol J, et al: The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia. 25:1869–1876. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hezaveh K, Kloetgen A, Bernhart SH, Mahapatra KD, Lenze D, Richter J, Haake A, Bergmann AK, Brors B, Burkhardt B, et al: Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. Haematologica. 101:1380–1389. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Tikhonenko TA and Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bueno MJ, Gómez de Cedron M, Gomez-López G, Pérez de Castro I, Di Lisio L, Montes-Moreno S, Martinez N, Guerrero M, Sanchez-Martinez R, Santos J, et al: Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood. 117:6255–6266. 2011. View Article : Google Scholar : PubMed/NCBI | |
Oduor CI, Kaymaz Y, Chelimo K, Otieno JA, Ongecha JM, Moormann AM and Bailey JA: Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma. BMC Cancer. 17:7612017. View Article : Google Scholar : PubMed/NCBI | |
Ott G, Rosenwald A and Campo E: Understanding MYC-driven aggressive B-cell lymphomas: Pathogenesis and classification. Blood. 122:3884–3891. 2013. View Article : Google Scholar : PubMed/NCBI | |
Robaina MC, Mazzoccoli L, Arruda VO, de Souza Reis FR, Apa AG, de Rezende LMM and Klumb CE: Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis. Exp Molec Pathol. 98:200–207. 2015. View Article : Google Scholar | |
Li JG, Ding Y, Huang YM, Chen WL, Pan LL, Li Y, Chen XL, Chen Y, Wang SY and Wu XN: FAMLF is a target of miR-181b in Burkitt lymphoma. Braz J Med Biol Res. 50:e56612017. View Article : Google Scholar : PubMed/NCBI | |
Doose G, Haake A, Bernhart SH, Lopez C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A, et al: MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 112:E5261–5270. 2015. View Article : Google Scholar : PubMed/NCBI | |
Watkins AJ, Hamoudi RA, Zeng N, Yan O, Huang Y, Liu H, Zhang J, Braggio E, Fonseca R, de Level L, et al: An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One. 7:e449972012. View Article : Google Scholar : PubMed/NCBI | |
Thorns C, Kuba J, Bernard V, Senft A, Szymczak S, Feller AC and Bernd HW: Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma. Virchows Arch. 460:371–377. 2012. View Article : Google Scholar : PubMed/NCBI | |
Fernández C, Bellosillo B, Ferraro M, Seoane A, Sánchez-González B, Pairet S, Pons A, Barranco L, Vela MC, Gimeno E, et al: MicroRNAs 142-3p, miR-155 and miR-203 are deregulated in gastric MALT lymphomas compared to chronic gastritis. Cancer Genomics Proteomics. 14:75–82. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liu TY, Chen SU, Kuo SH, Cheng AL and Lin CW: E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: Possible correlation with stage and treatment response. Modern Pathol. 23:1507–1517. 2010. View Article : Google Scholar | |
McKay P, Fielding P, Gallop-Evans E, Hall GW, Lambert J, Leach M, Marafioti T and McNamara C: Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. Br J Haematol. 172:32–43. 2016. View Article : Google Scholar : PubMed/NCBI | |
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H and Thiele J: WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization, International Agency for Research on Cancer (Revised 4th edition). 2018. | |
Re D, Roman TK, Behringer K and Diehl V: From Hodgkin disease to Hodgkin lymphoma: Biologic insights and therapeutic potential. Blood. 105:4553–4560. 2005. View Article : Google Scholar : PubMed/NCBI | |
Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S, Kroesen BJ, Kok K and van den Berg A: A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res. 37:e1372009. View Article : Google Scholar : PubMed/NCBI | |
Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E and Monzo M: Regulation of JAK2 by miR-135a: Prognostic impact in classic Hodgkin lymphoma. Blood. 114:2945–2951. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LH, Chadburn A, Tuschl T, Knowles DM and Tam W: MicroRNA mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: A potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 173:242–252. 2008. View Article : Google Scholar : PubMed/NCBI | |
Leucci E, Zriwil A, Gregersen LH, Jensen KT, Obad S, Bellan C, Leoncini L, Kauppinen S and Lund AH: Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene. 31:5081–5089. 2012. View Article : Google Scholar : PubMed/NCBI | |
van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, Blokzijl T, Jacobs S, Kluiver J, Diepstra A, Maggio E and Poppema S: High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer. 37:20–28. 2003. View Article : Google Scholar : PubMed/NCBI | |
Metzler M, Wilda M, Busch K, Viehmann S and Borkhardt A: High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer. 39:167–169. 2004. View Article : Google Scholar : PubMed/NCBI | |
Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ and van den Berg A: Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 11:167–176. 2009. View Article : Google Scholar : PubMed/NCBI | |
Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, et al: MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 111:2825–2832. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M, et al: MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 162:336–347. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ben Dhiab M, Ziadi S, Louhichi T, Ben Gacem R, Ksiaa F and Trimeche M: Investigation of miR9-1, miR9-2 and miR9-3 methylation in Hodgkin lymphoma. Pathobiology. 82:195–202. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cao Z, Qiu J, Yang G, Liu Y, Luo W, You L, Zheng L and Zhang T: MiR-135a biogenesis and regulation in malignancy: A new hope for cancer research and therapy. Cancer Biol Med. 17:569–582. 2020.PubMed/NCBI | |
Solé C, Arnaiz E and Lawrie CH: MicroRNAs as biomarkers of B-cell lymphoma. Biomark Insights. Oct 16–2018.(Epub ahead of print). doi: 10.1177/1177271918806840. View Article : Google Scholar | |
The Leukemia Lymphoma Society, . Non Hodgkin Lymphoma. 2006. | |
Vose JM: Peripheral T-cell non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 22:997–1005. 2008. View Article : Google Scholar : PubMed/NCBI | |
Mei M and Zhang M: Non-coding RNAs in Natural Killer/T-cell lymphoma. Front Oncol. 9:5152019. View Article : Google Scholar : PubMed/NCBI | |
Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, Kopp KL, Vennegaard MT, Lauenborg B, Zibert JR, et al: Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 118:5891–5900. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K, Yamashita Y, Saitoh H, Kameoka Y and Shimizu N: Aberrant overexpression of microRNAs activate AKT signaling via downregulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 114:3265–3275. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhang X, Ji W, Huang R, Li L, Wang X, Li L, Fu X, Sun Z, Li Z, Chen Q and Zhang M: MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. Oncotarget. 7:53808–53819. 2016. View Article : Google Scholar : PubMed/NCBI | |
Motsch N, Alles J, Imig J, Zhu J, Barth S, Reineke T, Tinguely M, Cogliatti S, Dueck A, Meister G, et al: MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing. PLoS One. 7:e421932012. View Article : Google Scholar : PubMed/NCBI | |
Chen HH, Huang WT, Yang LW and Lin CW: The PTEN-AKT-mTOR/RICTOR pathway in nasal natural killer cell lymphoma is activated by miR-494-3p via PTEN but inhibited by miR-142-3p via RICTOR. Am J Pathol. 185:1487–1499. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liang L, Nong L, Zhang S, Zhao J, Ti H, Dong Y, Zhang B and Li T: The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res. 33:72014. View Article : Google Scholar : PubMed/NCBI | |
Huang WT and Lin CW: EBV-encoded miR-BART20-5p and miR-BART8 inhibit the IFN-γ-STAT1 pathway associated with disease progression in nasal NK-cell lymphoma. Am J Pathol. 184:1185–1197. 2014. View Article : Google Scholar : PubMed/NCBI | |
Alles J, Menegatti J, Motsch N, Hart M, Eichner N, Reinhardt R, Meister G and Grasser FA: miRNA expression profiling of Epstein-Barr virus-associated NKTL cell lines by Illumina deep sequencing. FEBS Open Bio. 6:251–263. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ramakrishnan R, Donahue H, Garcia D, Tan J, Shimizu N, Rice AP and Ling PD: Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas. PLoS One. 6:e272712011. View Article : Google Scholar : PubMed/NCBI | |
Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet. 374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C and Klibanski A: Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 282:24731–24742. 2007. View Article : Google Scholar : PubMed/NCBI | |
Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M and Bourantas KL: Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma. 8:171–175. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zhuang W, Ge X, Yang S, Huang M, Zhuang W, Chen P, Zhang X, Fu J, Qu J and Li B: Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription. Stem Cells. 33:1985–1997. 2015. View Article : Google Scholar : PubMed/NCBI | |
Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al: Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 106:11667–11672. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bennett CF, Baker BF, Pham N, Swayze E and Geary RS: Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol. 57:81–105. 2017. View Article : Google Scholar : PubMed/NCBI | |
Koch L: Functional genomics: Screening for lncRNA function. Nat Rev Genet. 18:702017. View Article : Google Scholar | |
Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al: Genome-Scale CRISPR-mediated control of gene repression and activation. Cell. 159:647–661. 2014. View Article : Google Scholar : PubMed/NCBI | |
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI | |
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI | |
Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI | |
Mattheolabakis G, Rigas B and Constantinides PP: Nanodelivery strategies in cancer chemotherapy: Biological rationale and pharmaceutical perspectives. Nanomedicine (Lond). 7:1577–1590. 2012. View Article : Google Scholar : PubMed/NCBI | |
Webster DM, Sundaram P and Byrne ME: Injectable nanomaterials for drug delivery: Carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm. 84:1–20. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fabbro C, Ali-Boucetta H, Da Ros T, Kostarelos K, Bianco A and Prato M: Targeting carbon nanotubes against cancer. Chem Commun (Camb). 48:3911–3926. 2012. View Article : Google Scholar : PubMed/NCBI | |
Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, Seidel GD, Yuldasheva N and Tamarkin L: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 16:6139–6149. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK and Kim DD: Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res. 24:2402–2411. 2007. View Article : Google Scholar : PubMed/NCBI | |
Markman JL, Rekechenetskiy A, Holler E and Ljubimova JY: Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 65:1866–1879. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bartolomé-Izquierdo N, de Yébenes VG, Álvarez-Prado AF, Mur SM, Lopez Del Olmo JA, Roa S, Vazquez J and Ramiro AR: miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood. 129:2408–2419. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, et al: LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 120:1678–1686. 2012. View Article : Google Scholar : PubMed/NCBI | |
Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M and Jackson AL: Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 183:428–444. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li J, Zou J, Wan X, Sun C, Peng F, Chu Z and Hu Y: The role of noncoding RNAs in B-cell lymphoma. Front Oncol. 10:5778902020. View Article : Google Scholar : PubMed/NCBI | |
Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, Liu Z, Xu Q, Liu S, Xiao D and Tao Y: Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 19:472020. View Article : Google Scholar : PubMed/NCBI | |
Lin R, Sampson JH, Li QJ and Zhu B: miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. Oncoimmunology. 4:e9908032015. View Article : Google Scholar : PubMed/NCBI |